Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Ventricular Ejection Fraction, LVF
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
This prospective, multicenter, cluster-randomized controlled study aims to evaluate the accuracy of an investigational artificial intelligence (AI) Software as a Medical Device (SaMD) designed to compute ejection fraction (EF)…
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement
- Trial name
- EFACT (NCT06699056)
- Testing
- 15-minutes of sitting during COR ECG Acquistion
- Where
- 8 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Coronary Heart Disease
Molecular Pathways Involved in Cardiac Remodeling in Patients With Chronic Heart Failure With Preserved Ejection Fraction by New Omics Technologies
Heart failure with preserved ejection fraction nowadays affects about half of all patients with heart failure. In the general population, the prevalence of this subclass of heart failure (HFpEF, ed.) increases as the age of…
- Trial name
- HFpEF (NCT05772754)
- Testing
- study of molecular and protein pathways
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Microvascular Coronary Dysfunction, Cardiovascular Disease
WISE CVD - Continuation (WISE HFpEF)
The Women's Ischemia Study Evaluation (WISE), a cohort study of over 1000 women, has made many contributions to the understanding of cardiovascular disease.
- Trial name
- NCT02582021
- Testing
- Coronary Angiography, Coronary Reactivity Testing, Cardiac Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Cedars-Sinai Medical Center
Heart Failure, Diastolic
Cardiac Magnetic Resonance Tomography for Heart Failure With Preserved Ejection Fraction
The diagnosis of heart failure with preserved ejection fraction has so far been made primarily according to criteria determined by echocardiography, or invasively by measuring the left ventricular filling pressures.
- Trial name
- NCT05322109
- Testing
- CMR
- Where
- Germany
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- German Heart Institute
Heart Failure With Preserved Ejection Fraction
Cilostazol for HFpEF
Determine if cilostazol improves symptoms and NTproBNP levels (heart failure blood marker) in heart failure with preserved ejection fraction (HFpEF) - a prevalent syndrome without targeted evidence-based treatment.
- Trial name
- NCT05126836
- Testing
- Cilostazol 100Mg Tab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Minnesota
Heart Failure
Ubiquinol Treatment in Patients With Heart Failure and Preserved Ejection Fraction
There are no studies specifically examining the effects of coenzyme Q (CoQ) treatment on echocardiographic indices of diastolic function in elderly patients with heart failure with preserved ejection fraction (HFPEF).
- Trial name
- NCT02779634
- Testing
- ubiquinol
- Volunteers
- 60 people
- Sponsor
- Hadassah Medical Organization
Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction
Incretin Therapies in Obesity-related HFpEF
The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume.
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Trial name
- NCT07554638
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Columbia University
Heart Failure, Heart Failure Preserved Ejection Fraction
Exercise, Mediterranean Diet and Inflammation in Heart Failure
This randomized clinical trial will test whether a multimodal anti-inflammatory program added to standard treatment improves the prognosis of patients with heart failure who have recently been hospitalized or visited the…
- Conditions
- Heart Failure, Heart Failure Preserved Ejection Fraction, Heart Failure, Diastolic (HFpEF), Chronic Inflammation
- Trial name
- FLARE-HF (NCT07885514)
- Testing
- Structured exercise training program, Mediterranean diet counseling, Standard heart failure management
- Volunteers
- 214 people
- Sponsor
- Hospital Severo Ochoa
Heart Failure With Preserved Ejection Fraction
Study of the Prognosis of Patients With Heart Failure With Preserved Ejection Fraction
Study of the prognosis of patients with heart failure with preserved ejection fraction
- Trial name
- NCT05496439
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Chongqing Medical University
Heart Failure With Preserved Ejection Fraction, Chronic Pulmonary Thromboembolism (Disorder)
The Prognostic Role and Diagnostic Efficacy of Exercise Right Heart Catheterization With a Simultaneous Echocardiography in Patients With Dyspnea on Exertion
To evaluate the role of exercise hemodynamic testing in the diagnostic workup for patients with dyspnea on exertion referred to the catheterization lab.
- Trial name
- EX_CATH (NCT05490901)
- Testing
- Exercise hemodynamic test
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
Diastolic Heart Failure, Diastolic Dysfunction
CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)
The study objective is to demonstrate safety and feasibility of the CORolla® TAA during 12 months of follow up, and to evaluate the performance of the therapy in relieving symptoms and restore diastolic function in patients with…
- Trial name
- NCT02499601
- Testing
- CORolla™ TAA device
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- CorAssist Cadiovascular Ltd.
Cirrhotic Cardiomyopathy, Empagliflozin
DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
1. This proposed double-blind placebo controlled randomized controlled trial incorporates recent advances in management of heart failure and portal hypertension using the SGLT-2 inhibitor i.e. EMPAGLIFLOZIN.
- Conditions
- Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors, Cirrhosis
- Trial name
- DICE (NCT07322237)
- Testing
- Empagliflozin + Carvedilol, Carvedilol
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Heart Failure With Preserved Ejection Fraction
Right Ventricular Function and Pulmonary Hypertension in HFpEF
In patients with heart failure and preserved ejection fraction (HFpEF) right ventricular (RV) systolic and diastolic dysfunction are prognostically and functionally relevant factors but have mechanistically been neglected so far.
- Trial name
- HFpEF-PHT (NCT05055180)
- Testing
- Invasive hemodynamics and myocardial biopsies
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Heart Center Leipzig - University Hospital
Heart Failure With Preserved Ejection Fraction
Endovascular GSN Ablation in Subjects With HFpEF
The purpose of this study is to evaluate the safety and potential benefits of single-side block of a nerve that connects to the intestines, liver and spleen called the "greater splanchnic nerve" for the treatments of patients…
- Trial name
- NCT04287946
- Testing
- Ablation
- Where
- 3 sites in Czechia, Georgia
- Volunteers
- 30 people
- Sponsor
- Axon Therapies, Inc.
Transthyretin Amyloidosis, Heart Failure
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF)…
- Conditions
- Transthyretin Amyloidosis, Heart Failure, Heart Failure, Diastolic, Amyloidosis
- Trial name
- TTRinHFpEF (NCT05577819)
- Testing
- 99mTc-pyrophosphate Scintigraphy
- Where
- United States
- Volunteers
- 515 people
- Sponsor
- Massachusetts General Hospital
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test (6MWT) in patients with chronic heart failure (CHF) with preserved ejection…
- Trial name
- NCT03448406
- Testing
- Empagliflozin
- Where
- 108 sites in United States, Australia and 9 more
- Volunteers
- 315 people
- Sponsor
- Boehringer Ingelheim
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF Canada
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05332873
- Testing
- Rivet Shunt
- Where
- Canada
- Sponsor
- NXT Biomedical
Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials.
- Trial name
- EMPA-PRED (NCT06249945)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
HFpEF
Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction
What is HFpEF? In heart failure with preserved ejection fraction (HFpEF), the heart pumps well but struggles to relax and fill with blood between beats.
- Trial name
- APAVE (NCT07270536)
- Testing
- Accelerated pacing with AV-delay optimization during rest and light intensity cycling
- Where
- 2 sites in Belgium
- Volunteers
- 20 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven